Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies | terminated | Phase 1 / Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07028281 | A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors | recruiting | Phase 2 | 120 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 3, 2026 |
| clinicaltrials |
| NCT04238819 | A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma | completed | Phase 1 / Phase 2 | 47 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT04469530 | Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors(AflacST1903) | recruiting | Phase 2 | 55 | Emory UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06410209 | A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | recruiting | Phase 2 | 190 | Children's Oncology GroupNETWORK | 2 | Feb 27, 2026 | clinicaltrials |
| NCT07433283 | Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 54 | Sichuan Enray Pharmaceutical Sciences CompanyOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04233567 | Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations | completed | Phase 2 | 17 | Sameek RoychowdhuryOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06005974 | A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation | terminated | Phase 2 | 18 | Recursion Pharmaceuticals Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04282018 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | completed | Phase 1 / Phase 2 | 97 | BeiGeneINDUSTRY | 2 | Feb 20, 2026 | clinicaltrials |
| NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | not yet recruiting | Phase 1 / Phase 2 | 24 | University of ChicagoOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT07417501 | Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification | not yet recruiting | Phase 2 | 60 | Tongji HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT04041310 | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 115 | Nouscom SRLINDUSTRY | 6 | Feb 13, 2026 | clinicaltrials |
| NCT06358677 | Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Patients With Solid Tumors(FACE) | recruiting | Phase 2 | 25 | University of UtahOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07328217 | A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 203 | Dizal PharmaceuticalsINDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04078295 | A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 125 | Eisai Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | recruiting | Phase 1 / Phase 2 | 400 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06634849 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1). | recruiting | Phase 1 / Phase 2 | 30 | Pathios Therapeutics Pty LtdINDUSTRY | 1 | Feb 10, 2026 | clinicaltrials |
| NCT06534190 | CD8 PET Imaging in Metastatic Solid Tumours | recruiting | Phase 2 | 30 | University Medical Center GroningenOTHER | 3 | Feb 9, 2026 | clinicaltrials |
| NCT07392736 | A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 228 | Advenchen Laboratories, LLCINDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03465592 | Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | recruiting | Phase 1 / Phase 2 | 39 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07359066 | An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 210 | Shanghai SciBrunch Therapeutics Co., Ltd.INDUSTRY | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06771622 | Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 500 | FBD Biologics LimitedINDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07382531 | OH2 Injection in Combination With BS006 Injection for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05419375 | Screening Study for Participants With Malignant Tumors | completed | Phase 2 | 470 | Hoffmann-La RocheINDUSTRY | 26 | Feb 3, 2026 | clinicaltrials |
| NCT05756907 | Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 40 | Sonnet BioTherapeuticsINDUSTRY | 2 | Feb 3, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT05744427 | Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 725 | Jiangsu Alphamab Biopharmaceuticals Co., LtdINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | terminated | Phase 2 | 6 | Prelude TherapeuticsINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | GenmabINDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | recruiting | Phase 1 / Phase 2 | 110 | Auricula Biosciences Inc.INDUSTRY | 3 | Jan 29, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT07151040 | Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors(ODIN) | recruiting | Phase 1 / Phase 2 | 43 | One-carbon Therapeutics ABINDUSTRY | 3 | Jan 28, 2026 | clinicaltrials |
| NCT07371663 | An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 266 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03697304 | Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours | completed | Phase 2 | 211 | Boehringer IngelheimINDUSTRY | 3 | Jan 27, 2026 | clinicaltrials |
| NCT05867420 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 594 | AskGene Pharma, Inc.INDUSTRY | 2 | Jan 27, 2026 | clinicaltrials |
| NCT04504942 | Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors | completed | Phase 2 | 16 | CytoDyn, Inc.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05071209 | Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 31 | National Cancer Institute (NCI)NIH | 2 | Jan 23, 2026 | clinicaltrials |
| NCT07093970 | A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 343 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04617054 | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion | terminated | Phase 2 | 14 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04627740 | Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06553157 | Statins Effect on Incidence of Side Effects of Platinum Based Chemotherapy | completed | Phase 1 / Phase 2 | 56 | Minia UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06556108 | ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 5 | Xinqiao Hospital of ChongqingOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06959615 | A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration | recruiting | Phase 1 / Phase 2 | 334 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05388058 | Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06973564 | JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration | recruiting | Phase 1 / Phase 2 | 294 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT05163041 | Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression | active not recruiting | Phase 1 / Phase 2 | 200 | BicycleTx LimitedINDUSTRY | 2 | Jan 15, 2026 | clinicaltrials |
| NCT07339748 | A Clinical Study of ZL-85FA Tablets | not yet recruiting | Phase 1 / Phase 2 | 51 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2026source: clinicaltrials